Licensing income boosts Wilex in the first nine months

Wilex AG was boosted in the first nine months of 2011 by income from a licensing agreement for its lead cancer antibody with Prometheus Laboratories Inc (Nestle SA). Nine-month income was €5.6 million compared with €1.2 million a year earlier.